The FDA has issued a safety alert regarding Johnson & Johnson MedTech’s Automated Impella Controller (AIC), a key interface for Impella heart pumps used in mechanical circulatory support. The agency reported that the AIC may fail to detect connected pumps, potentially resulting in inadequate hemodynamic support. This issue poses significant risks, especially for patients in cardiogenic shock, where insufficient support can cause life-threatening injuries.
As of June 13, three deaths have been linked to this problem. J&J advised healthcare providers to keep backup AIC consoles available and follow specific troubleshooting steps during console transfers and case starts. No product recalls or removals have been initiated.
J&J confirmed a low occurrence rate of 0.02% based on complaint reviews since 2021 and emphasized ongoing efforts to educate clinicians to ensure patient safety. The Impella technology was acquired by J&J in 2022 from Abiomed.
Follow MEDWIRE.AI for regulatory updates in cardiovascular device safety.
